BMRA - Biomerica, Inc.
Chart Events
Triple Moving Average Crossover
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 1.3300 |
| Open | 1.3400 |
| Bid | 1.3900 x 1000 |
| Ask | 1.4400 x 1000 |
| Day's Range | 1.2900 - 1.4400 |
| 52 Week Range | 1.0800 - 5.2500 |
| Volume | |
| Avg. Volume | 39,638 |
| Market Cap | 23.382M |
| Beta (5Y Monthly) | -0.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5400 |
| Earnings Date | Aug 28, 2023 - Sep 01, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.00 |
Fair Value
Related Research
GlobeNewswireinFoods® IBS Test Now Validated for Use with Simple Finger Stick Whole Blood Collection Technology
Gastro Health, a leading gastroenterology group, plans to utilize this simplified blood collection method when recommending the inFoods® IBS to their patients Biomerica also announced that inFoods® IBS clinical trial data was presented at the DDW conference May 8th.The data showed that the inFoods® IBS treatment diet significantly improved several key IBS symptoms including Abdominal Pain Intensity (API)inFoods IBS showed improvement in API similar to, and in some cases better than, current IBS
- GlobeNewswire
Biomerica’s inFoods® IBS test is now available at Gastro Health, providing a revolutionary new treatment for patients suffering from Irritable Bowel Syndrome (IBS).
Gastro Health is a leading gastroenterology group with over 380 GI physicians in the United StatesClinical study results show patients who eliminated foods as determined by the inFoods® IBS test experience significant improvement in IBS Symptoms Including Abdominal Pain Intensity (API) IRVINE, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic products, is pleased to announce that inFoods® IBS, a revolutiona
- GlobeNewswire
Biomerica Reports Q3 Fiscal 2023 Results
For the nine months ended February 28, 2023 vs. the same period in 2022, revenues, excluding sales of Covid-related products, increased by 16%.InFoods® IBS Laboratory Developed Test (LDT) validation testing at the CLIA Lab has been completed, patient testing now underway. IRVINE, Calif., April 14, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical diagnostic and therapeutic products, today announced its fiscal third quarter and nine month results ended
- GlobeNewswire
Biomerica announces the Launch of InFoods IBS as a Laboratory Developed Test (LDT); First patient samples have been processed
InFoods® IBS LDT validation testing at the CLIA Lab is completed and the product is now being offered commerciallyClinical trial data shows InFoods® IBS treatment diet significantly improved several key IBS symptoms including Abdominal Pain Intensity (API)The improvement in API for patients in the treatment arm versus the placebo arm was similar to, and in some cases better than, the current IBS drugs in the market. IRVINE, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA
- GlobeNewswire
Biomerica Announces Closing of $8 Million Underwritten Public Offering of Common Stock
IRVINE, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) (“Biomerica”), a global provider of advanced medical products, announced today the closing of its previously announced underwritten public offering of an aggregate of 3,333,333 shares of its common stock, par value $0.08 per share, at a price to the public of $2.40 per share for total gross proceeds of $8 million, before deducting underwriting discounts and commissions and other offering-related expenses payable by
- GlobeNewswire
Biomerica Announces Pricing of $8 Million Underwritten Public Offering of Common Stock
IRVINE, Calif., March 03, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) (“Biomerica”), a global provider of advanced medical products, announced today the pricing of its previously announced underwritten public offering. Biomerica is offering an aggregate of 3,333,333 shares of its common stock, par value $0.08 per share, at a price to the public of $2.40 per share. All shares of common stock in the offering are being offered by Biomerica. Craig-Hallum Capital Group LLC is acting as so
- GlobeNewswire
Biomerica Announces Proposed Underwritten Public Offering of Common Stock
IRVINE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) (“Biomerica”), a global provider of advanced medical products, announced today that it has commenced an underwritten public offering of its common stock. All shares of common stock in the proposed offering are being offered by Biomerica. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Simply Wall St.We're Keeping An Eye On Biomerica's (NASDAQ:BMRA) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
GlobeNewswireBarnwell Industries, Inc. Reaches Cooperation and Support Agreement With its Largest Stockholders
Agrees to Reconstitute Its Board and Extend Standstill AgreementHONOLULU, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Barnwell Industries, Inc. (NYSE-American: BRN) (“Barnwell” or the “Company”) announce today that it has entered into a cooperation and support agreement (the “Agreement”) with its two largest stockholders, Alexander C. Kinzler, who beneficially owns approximately 9.3% of the Company’s outstanding common stock, and MRMP-Managers LLC, Ned L. Sherwood Revocable Trust, and Ned L. Sherwood (col
- GlobeNewswire
Biomerica Reports Financial Results for Fiscal 2023 Second Quarter Ended November 30, 2022
InFoods® IBS Data Receives American College of Gastroenterology Presidential Award (ACG) Following Presentation at Annual Scientific Meeting Trial Data Shows InFoods® IBS Treatment Diet Significantly Improved Several IBS Symptoms Including Abdominal Pain Intensity (API): In Some Cases Better Than Certain Currently Marketed Drugs Launch of InFoods® IBS Lab Developed Test Expected in Fiscal 3Q Amazon Now Fulfills Sales of Aware® Breast Self Exam and EZ Detect™ Colon Disease Tests IRVINE, Calif., J
- GlobeNewswire
Biomerica Appoints Mayo Clinic Gastroenterologist, Dr. Brian E. Lacy, to the Company’s Scientific Advisory Board
Dr. Lacy is the former co-Editor in Chief of the American Journal of Gastroenterology, the former Editor in Chief of Clinical and Translational Gastroenterology, and has served as the co-Chairman for the Rome IV Committee on Functional Bowel Disorders. Dr. Lacy has authored over 225 peer reviewed articles IRVINE, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) appointed prominent physician and key opinion leader Brian E. Lacy, M.D., Ph.D., a board-certifi
- GlobeNewswire
Biomerica Receives KFDA and Ministry of Health Approval for Colorectal Screening and Breast Screening Tests in Saudi Arabia and UAE
Expands Commercialization Efforts in Areas with High Unmet NeedsIRVINE, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) received clearance from the Kingdom of Saudi Arabia Food and Drug Administration (KFDA), and the United Arab Emirates (UAE) Ministry of Health and Prevention (MOHAP) for the EZ Detect™ Colon Disease test and the Aware® Breast Self Exam device. The Company is working with distribution partners to launch the products in these countries and
- Simply Wall St.
We Think Shareholders May Consider Being More Generous With Biomerica, Inc.'s (NASDAQ:BMRA) CEO Compensation Package
Shareholders will be pleased by the robust performance of Biomerica, Inc. ( NASDAQ:BMRA ) recently and this will be...
- GlobeNewswire
Biomerica InFoods® IBS Data Presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting
ACG Presidential Award Received for the InFoods® IBS Data Presented at the American College of Gastroenterology (ACG) Annual Scientific MeetingThe Presented Clinical Study Data Showed InFoods® IBS Provided Significant Improvement in Several IBS Symptoms Including Abdominal Pain Intensity (API), Which, in Some Cases, Were Better Than Current Drugs in the MarketInFoods® IBS Clinical Research Data Is Also Featured in Medscape and Gastroenterology Advisor, two leading Medical Trade and News Publicat
BenzingaWalmart Expands Sales Of Biomerica's Aware Breast Self Exam To 2400 Stores
Biomerica Inc (NASDAQ: BMRA) said under a General Merchandise Supplier Agreement with Walmart Inc (NYSE: WMT), its Aware Breast Self-Exam device will now be sold in over 2400 Walmart’s retail stores. Walmart began selling the Aware product online through Walmart.com in July. The retailer will now sell the product at approximately 50% of their retail store locations. Also Read: Walmart Acquires Warehouse Automation Firm Alert Innovation Biomerica has received and shipped an Initial stocking order
- GlobeNewswire
Walmart to Expand Sales of Biomerica’s Aware® Breast Self Exam; Product will now be available in over 2400 Walmart stores
Simple at-home device to increase sensitivity in breast self-examsEarly detection of breast cancer saves livesAbout 80% of breast cancer is detected by women themselves who notice changes in their breast IRVINE, Calif., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that under a General Merchandise Supplier Agreement with Walmart, the Company’s Aware® Breast Self Exam device will now be sold in over 2400 Walmart’s retail stores. In July, the Comp
- GlobeNewswire
Biomerica Reports 30% Increase in Revenues for Fiscal Q1 2023 vs. Fiscal Q1 2022
Notice of Patent Allowance in Australia containing broad claims pertaining to treating ADD/ADHD using the InFoods® Technology Notice of Patent Allowance in Japan containing broad claims pertaining to treating Depression using the InFoods® Technology IRVINE, Calif., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today reported net sales for the three months ended August 31, 2022 of $1.67 million, versus net sales of $1.26 million
- Simply Wall St.
Those who invested in Biomerica (NASDAQ:BMRA) five years ago are up 39%
Passive investing in index funds can generate returns that roughly match the overall market. But you can do a lot...
- GlobeNewswire
Biomerica’s Aware® Breast Self Exam and EZ Detect™ Colon Disease Test Now Available on Amazon and Fulfilled by Amazon
Aware® is a simple at-home device to increase sensitivity in breast self-exams. About 80% of breast cancer is detected by women themselves who notice changes in their breast.EZ Detect™ is a simple 2-minute, at-home test which detects an early warning sign of colorectal cancer IRVINE, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that the Company’s Aware® Breast Self Exam device and EZ Detect Colon Disease test are now being sold on Amaz
- Simply Wall St.
We're Interested To See How Biomerica (NASDAQ:BMRA) Uses Its Cash Hoard To Grow
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
- GlobeNewswire
Biomerica Plans Launch of InFoods® IBS Test; Names Robert Carlson as Chief Commercial Officer
InFoods® IBS commercial launch and revenues expected before the close of calendar year 2022Mr. Carlson is an accomplished and performance-driven Commercial and Corporate Strategy and Development Executive IRVINE, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced plans to launch its InFoods® IBS test before calendar year end. The test will be performed in a CLIA-certified, high-complexity laboratory facility and offered as a laboratory develo
- GlobeNewswire
Biomerica Reports Fiscal 2022 Year End Results
Revenues increase 162% for fiscal 2022 vs fiscal 2021 Revenues for fiscal Q4 2022 up 403% vs. fiscal Q4 2021 IRVINE, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products, today reported its fiscal 2022 financial results. Net sales for the fiscal year ended May 31, 2022 were $18.9 million as compared to net sales of $7.2 million in fiscal 2021, an increase of $11.7 million, or 162%. Net loss was $4.6 million for f
BenzingaWalmart to Start Selling Biomerica's Aware Breast Self Exam Devices
Biomerica Inc (NASDAQ: BMRA) announced that its Aware Breast Self Exam device will now be sold in Walmart Inc's (NYSE: WMT) retail system. The Biomerica FDA-cleared Aware Breast Self Exam device is a way for women to enhance tactile sensitivity to changes or irregularities in breast tissue, making breast self-exams easy and convenient. The Aware device can facilitate an effective self-exam and serve as a reminder to perform a breast self-exam every month. Biomerica has now shipped its first orde
- GlobeNewswire
Walmart to Begin Selling Biomerica’s Aware® Breast Self Exam
Simple at-home device to increase sensitivity in breast self examsEarly detection of breast cancer saves livesBreast Cancer accounts for 1 in 3 new cases of cancer in women annually IRVINE, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that under a General Merchandise Supplier Agreement with Walmart, the Company’s Aware® Breast Self Exam device will now be sold in Walmart’s retail system. Biomerica has now shipped its first orders of the
- GlobeNewswire
Biomerica to Participate at BTIG Biotech Conference
IRVINE, Calif., June 23, 2022 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced that the Company’s CEO will participate at the 2022 BTIG Biotechnology Conference being held in person in New York City on Monday, August 8th and Tuesday August 9th, 2022. The Company’s CEO will also be available for in-person one-on-one meetings at the conference. About Biomerica NASDAQ: BMRA) Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufa